Our Science

Novel drugs to treat acute organ inflammation

Explore Arch Biopartners platforms, teams and publications

Arch is developing new drugs, led by LSALT peptide, that are:

  • designed to inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP1) pathway and,
  • relevant for common organ injuries and diseases where organ inflammation is an unmet problem with no effective treatments in the market today.
About LSALT peptide

Following our scientists’ identification of DPEP1 as an adhesion receptor in the lungs, kidneys and liver and their discovery that DPEP1 was shown to be the target of LSALT peptide (Cell 2019). Arch believes that the drug has the potential to deliver a major breakthrough in the treatment of diseases where inflammation plays a major role.

In 2024, the company is sponsoring a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). The CS-AKI trial began dosing patients in March 2024. The trial began with three active hospital sites in Turkey with a hospital site in Canada also joining in March 2024. The complete study is planned to include up to 240 patients in Turkey, Canada and the United States.

Find out more about ongoing LSALT peptide development and clinical trials.

Additional programs not currently under development:
  • AB569, a potential new treatment for antibiotic resistant bacterial wound infections; and,
  • ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
An experienced team of scientists with an executive, board and advisors bringing deep scientific, pharmaceutical, biotechnology and corporate financial experience.
Science and Research Teams
  • Current work on LSALT Peptide is directed by Arch’s Treatments for Inflammation Team, led by Dr. Daniel Muruve Ph. D., Dr. Justin Macdonald Ph. D. and Dr. Arthur Lau Ph. D, who are primarily based at the University of Calgary. David Luke, BScPhm, PharmD, is a Strategic Advisor working to support the Board of Directors and the company’s ongoing clinical trials with LSALT peptide.
  • The DPEP1 Inflammation Pathway and LSALT Peptide (Metablok) were discovered by the Metablok team – Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D. and Jennifer Rahn B Sc., M Sc. at the University of Calgary.

The Arch Science team also includes:

And, until his passing Dr. Daniel (Dr.Dan) J. Hassett Ph.D. (May 1958-April 2022), who led the work on AB569 at the University of Cincinnati.

The Arch Biopartners Science Teams have all participated and authored key papers and journal publications as a core part of their ongoing scientific research, discoveries and development.
  • Treatments for Inflammation publications surrounding the development of LSALT Peptide (Metablok) as a treatment for inflammation with broad application to prevent organ and tissue injury
  • AB569 publications describing AB569 as a novel bactericidal treatment for treatment resistant bacteria and Respiratory Pseudomonas
  • BORG Peptide publications discussing a peptide-based biological coating for enhanced corrosion resistance, strength and control of adhesion of bacteria and microbes.
  • Brain Tumor Stem Cell Targeting publications describe the development of a peptide-based delivery platform for targeting malignant brain tumors

Latest Scientific Publications

Publications Archives